SLC5A2 and hydrops fetalis: Emerging therapies, such as angiotensin receptor neprilysin inhibitors (ARNI) and sodium-glucose cotransporter 2 (SGLT2) inhibitors, have demonstrated efficacy in HF management in other populations [70].